Our primary clinical outcome for treatment continuation was at least 30% reduction in mean MMD as per NICE (National Institute for Health and Care Excellence) guidelines on CGRP mAbs therapies in CM in the United Kingdom [17, 18]. The gene discussed is CALCA; the disease is cutaneous mastocytosis.